Clinical Trial Update: 4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability results from a 4-week study in patients with mild-to-moderate Alzheimer's disease, sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: AstraZeneca | Conditions: Mild to Moderate Alzheimer's Disease | Phase 2 | Status: COMPLETED